A cross‐sectional survey to assess community attitudes to introduction of Human Papillomavirus vaccine
Authors:
- 1 June 2007
- journal article
- Published by Elsevier in Australian and New Zealand Journal of Public Health
- Vol. 31 (3) , 235-242
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trialThe Lancet, 2006
- HPV-mediated transformation of the anogenital tractJournal of Clinical Virology, 2005
- Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialThe Lancet, 2004
- Human papillomavirus, smoking, and sexual practices in the etiology of anal cancerCancer, 2004
- Papillomavirus vaccines in clinical trialsThe Lancet Infectious Diseases, 2003
- Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysisBritish Journal of Cancer, 2003
- A Controlled Trial of a Human Papillomavirus Type 16 VaccineNew England Journal of Medicine, 2002
- Human papillomavirus infections: Epidemiology, pathogenesis, and host immune responseJournal of the American Academy of Dermatology, 2000
- Relation of human papilloma virus status to cervical lesions and consequences for cervical-cancer screening: a prospective studyThe Lancet, 1999
- Basaloid Squamous Cell Carcinoma: A Distinctive Human Papilloma Virus-Related Penile NeoplasmAmerican Journal of Surgical Pathology, 1998